These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9658914)

  • 1. [Thyroid cancer: metabolic treatment and follow-up using thyroglobulin levels and I-131 gammagraphy].
    Lampreave JL; Trampal C; Domínguez P; Bittini A
    Rev Clin Esp; 1998 May; 198(5):307-15. PubMed ID: 9658914
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current state of the treatment of thyroid cancer].
    Paches AI; Liubaev VL; Shental' VV; Pustynskiĭ IN; Abdullin NA
    Vopr Onkol; 1998; 44(5):562-6. PubMed ID: 9884715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of serum thyroglobulin determination in the follow-up of differentiated carcinomas of the thyroid].
    Secades Ariz I; Pérez Piqueras JL; Labanda Tejedor P; Cordero Peinado J
    An Med Interna; 1988 Sep; 5(9):439-43. PubMed ID: 2856622
    [No Abstract]   [Full Text] [Related]  

  • 4. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
    Pacini F; Schlumberger M; Dralle H; Elisei R; Smit JW; Wiersinga W;
    Eur J Endocrinol; 2006 Jun; 154(6):787-803. PubMed ID: 16728537
    [No Abstract]   [Full Text] [Related]  

  • 5. [Role of the nuclear medicine in the treatment of thyroid carcinoma].
    Börner W; Reiners C
    Med Klin; 1980 Jan; 75(2):80-7. PubMed ID: 7374606
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.
    Simon D; Körber C; Krausch M; Segering J; Groth P; Görges R; Grünwald F; Müller-Gärtner HW; Schmutzler C; Köhrle J; Röher HD; Reiners C
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):775-82. PubMed ID: 12029551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical changes in iodine-131 scintigraphic findings in advanced follicular thyroid cancer.
    Krishna L; Dadparvar S; Brady LW; Micaily B; Meihofer M; Slizofski WJ; Brown SJ; Chevres A; Roman R; Khan AS
    J Nucl Med; 1993 Sep; 34(9):1574-6. PubMed ID: 8355078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of medullary carcinoma of the thyroid with I-131 MIBG.
    Thomas CC; Cowan RJ; Albertson DA; Cooper MR
    Clin Nucl Med; 1994 Dec; 19(12):1066-8. PubMed ID: 7874804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radionuclides and therapy of thyroid cancer.
    O'Doherty MJ; Nunan TO; Croft DN
    Nucl Med Commun; 1993 Sep; 14(9):736-55. PubMed ID: 8233239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative strategies for less common thyroid cancers.
    Zeyher A
    J Nucl Med; 1998 Sep; 39(9):11N-12N, 17N. PubMed ID: 9744327
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
    Muratet JP; Daver A; Minier JF; Larra F
    J Nucl Med; 1998 Sep; 39(9):1546-50. PubMed ID: 9744340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of thyroid cancer patients with favorable prognostic indicators.
    Leboulleux S; Baudin E; Schlumberger M
    Ann Endocrinol (Paris); 2003 Feb; 64(1):64-7. PubMed ID: 12707639
    [No Abstract]   [Full Text] [Related]  

  • 14. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
    Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
    Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
    Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
    Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine ablation outcomes after imaging with 123I or 131I: is no news good news?
    Burniston MT; Wilson DJ
    J Nucl Med; 2008 Jan; 49(1):166; author reply 166-7. PubMed ID: 18165699
    [No Abstract]   [Full Text] [Related]  

  • 17. [Rational basis for the therapy of differentiated carcinoma of the thyroid].
    Nosari I; Tidone L; Ferrari L; Montini M; Sileo F; Pagani G; Gelli D
    Recenti Prog Med; 1984; 75(7-8):758-74. PubMed ID: 6438737
    [No Abstract]   [Full Text] [Related]  

  • 18. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
    Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
    J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of postoperative 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer.
    Baskin HJ
    Thyroid; 1994; 4(3):239-42. PubMed ID: 7833657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.